ArticleHealth science reports2026
The Epidemiology of HIV-1 Resistance to Two-Drug Regimens in Multicenter Cohort From Poland-A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06661317 (Presence of HIV-1 DRMs As a Risk Factor of Failure of Two Drugs Based ART Regimens, Including LAI ART, in Cohorts of Primary and Secondary DRMs.), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Presence of HIV-1 DRMs As a Risk Factor of Failure of Two Drugs Based ART Regimens, Including LAI ART, in Cohorts of Primary and Secondary DRMs.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Concerns about antiretroviral therapy failure are growing among people with HIV receiving two-drug regimens, as these schemes include fewer active agents, while the prevalence of transmitted resistance in HIV-1 continues to increase. Therefore, we aimed to assess the epidemiology of HIV-1 drug resistance mutations to the most commonly used two-drug regimens, consisting of oral dolutegravir plus lamivudine and injectable cabotegravir plus rilpivirine. Methods: In a multicenter, cross-sectional study conducted from January 2023 to March 2024, the frequency of HIV-1 resistance mutations to antiretrovirals was evaluated. Analyses were performed for drugs used in two-drug regimens, separately in treatment-naïve and treatment-experienced patients. Results: In a total of 333 patients included, 82% were treatment-naïve and sub-subtype A6 was responsible for 49.8% of infections. In treatment naïve patients, the frequency of transmitted major mutations to at least one agent ranged from 1.5% for dolutegravir plus lamivudine to 4.4% for cabotegravir plus rilpivirine. In treatment-experienced individuals with antiretroviral failure or who interrupted the treatment, the frequency of acquired major mutations to at least one agent was 6.7% for cabotegravir plus rilpivirine and 11.7% for dolutegravir plus lamivudine. In the latter subgroup, the frequency of any acquired resistance mutations (major and accessory) reached 16.7-23.3%. Conclusions: The integrase genotyping provides wide insight in a variable infection epidemiology and new therapeutic schemes. In our cohort, transmitted resistance to two-drug regimens in treatment-naïve individuals appears uncommon, with the frequency of 0.7-4.4%. However, in patients who interrupted the treatment or who experienced virological failure, all acquired resistance mutations are present in almost one-fourth of individuals, thus selective pressure from antiretroviral therapy warrants continuous surveillance. ClinicalTrialsgov Identifier: NCT06661317.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.